Stanleick replaces Clint Carnell, who left the company on Dec. 31, “by mutual agreement” between him and the company’s board of directors, according to documents filed with the Securities and Exchange Commission.
Brent Saunders, Beauty Health’s executive chairman, is serving as the interim chief executive.
Stanleick was at Coty Inc. since 2017, serving as the beauty company’s executive vice president of Americas region since May 2020. He also served as the chief executive for Coty’s joint venture with Kylie Jenner Beauty and oversaw the company’s minority stake in Kim Kardashian West’s makeup business.
Stanleick also spent nearly five years at Coach Inc., overseeing its Europe and Southeast Asia-Pacific businesses. Prior to Coach, he worked for 13 years at L’Oreal overseeing Europe, Russia and Asia.
“Andrew’s extensive knowledge of the beauty and retail industries, his high-impact global leadership, proven track record in international markets and in broadening brand awareness are invaluable as we continue to expand the beauty health category that we created,” Saunders said in a statement. “His two decades of international experience and innovative beauty marketing prowess uniquely position Andrew to build upon our platform and community to drive our growth as we capitalize on significant opportunities, especially in Asia. We are at a pivotal point in investing in our digital marketing and our infrastructure to expand our footprint globally, and Andrew will be instrumental to executing against our strategic initiatives.”
Beauty Health, formerly known as HydraFacial, makes $30,000 devices that estheticians use to clean and hydrate skin using patented technology and serums.
The company imports components from China and performs final assembly at its facilities in the Long Beach area. About half of the company’s revenue comes from what it calls “consumables,” including single-use products such as the extraction tips that come in direct contact with a client’s skin, as well as hydration serums and its Keravive scalp treatment.
The company, which has about 500 employees, debuted on the Nasdaq in May. Its market value has dropped from $3 billion to $2 billion since August.